90Y-ibritumomab tiuxetan radiotherapy as first-line therapy for early stage low-grade B-cell lymphomas, including bulky disease

Felipe Samaniego; Zuzana Berkova; Jorge E. Romaguera; Nathan Fowler; Michelle A. Fanale; Barbara Pro; Jatin J. Shah; Peter Mclaughlin; Lalit Sehgal; Vijairam Selvaraj; Frank K. Braun; Rohit Mathur; Lei Feng; Sattva S. Neelapu; Larry W. Kwak

doi:10.1111/bjh.13021

⁹⁰Y-ibritumomab tiuxetan radiotherapy as first-line therapy for early stage low-grade B-cell lymphomas, including bulky disease

Felipe Samaniego^*, Zuzana Berkova, Jorge E. Romaguera, Nathan Fowler, Michelle A. Fanale, Barbara Pro, Jatin J. Shah, Peter Mclaughlin, Lalit Sehgal, Vijairam Selvaraj, Frank K. Braun, Rohit Mathur, Lei Feng, Sattva S. Neelapu, Larry W. Kwak

^*Corresponding author for this work

Medicine, Hematology Oncology Division

Research output: Contribution to journal › Article › peer-review

24 Scopus citations

Abstract

⁹⁰Y-ibritumomab-tiuxetan (⁹⁰YIT) was used as a first-line therapy for patients with early-stage follicular lymphoma (FL) or marginal zone B-cell lymphoma (MZL). Thirty-one patients were treated, with an overall 3-month response rate of 100% (68% complete response, 29% unconfirmed complete response and 3% partial response). At a median follow-up of 56 months, ten patients (32%) had disease relapse or progression. The progression-free rates at 3 and 5 years were lower in males, patients with FL, stage II diseaseand non-bulky disease, although they did not reach statistical significance. Grade 3-4 neutropenia, thrombocytopenia and anaemia were 61%, 35%, and 3%, respectively. ⁹⁰YIT was well tolerated, including in those patients over 60 years old, and achieved high response rates in patients with early-stage low-grade B-cell lymphomas. Bulky disease did not adversely affect tumour response.

Original language	English (US)
Pages (from-to)	207-213
Number of pages	7
Journal	British Journal of Haematology
Volume	167
Issue number	2
DOIs	https://doi.org/10.1111/bjh.13021
State	Published - Oct 1 2014

Keywords

Follicular
Marginal zone
Myelosuppression
Radiation
Zevalin

ASJC Scopus subject areas

Hematology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1111/bjh.13021

Cite this

Samaniego, F., Berkova, Z., Romaguera, J. E., Fowler, N., Fanale, M. A., Pro, B., Shah, J. J., Mclaughlin, P., Sehgal, L., Selvaraj, V., Braun, F. K., Mathur, R., Feng, L., Neelapu, S. S., & Kwak, L. W. (2014). ⁹⁰Y-ibritumomab tiuxetan radiotherapy as first-line therapy for early stage low-grade B-cell lymphomas, including bulky disease. British Journal of Haematology, 167(2), 207-213. https://doi.org/10.1111/bjh.13021

@article{c71b78d49ad54b3b9b09f9f0e4dc443d,

title = "90Y-ibritumomab tiuxetan radiotherapy as first-line therapy for early stage low-grade B-cell lymphomas, including bulky disease",

abstract = "90Y-ibritumomab-tiuxetan (90YIT) was used as a first-line therapy for patients with early-stage follicular lymphoma (FL) or marginal zone B-cell lymphoma (MZL). Thirty-one patients were treated, with an overall 3-month response rate of 100% (68% complete response, 29% unconfirmed complete response and 3% partial response). At a median follow-up of 56 months, ten patients (32%) had disease relapse or progression. The progression-free rates at 3 and 5 years were lower in males, patients with FL, stage II diseaseand non-bulky disease, although they did not reach statistical significance. Grade 3-4 neutropenia, thrombocytopenia and anaemia were 61%, 35%, and 3%, respectively. 90YIT was well tolerated, including in those patients over 60 years old, and achieved high response rates in patients with early-stage low-grade B-cell lymphomas. Bulky disease did not adversely affect tumour response.",

keywords = "Follicular, Marginal zone, Myelosuppression, Radiation, Zevalin",

author = "Felipe Samaniego and Zuzana Berkova and Romaguera, {Jorge E.} and Nathan Fowler and Fanale, {Michelle A.} and Barbara Pro and Shah, {Jatin J.} and Peter Mclaughlin and Lalit Sehgal and Vijairam Selvaraj and Braun, {Frank K.} and Rohit Mathur and Lei Feng and Neelapu, {Sattva S.} and Kwak, {Larry W.}",

note = "Publisher Copyright: {\textcopyright} 2014 John Wiley & Sons Ltd.",

year = "2014",

month = oct,

day = "1",

doi = "10.1111/bjh.13021",

language = "English (US)",

volume = "167",

pages = "207--213",

journal = "British Journal of Haematology",

issn = "0007-1048",

publisher = "John Wiley and Sons Inc.",

number = "2",

}

Samaniego, F, Berkova, Z, Romaguera, JE, Fowler, N, Fanale, MA, Pro, B, Shah, JJ, Mclaughlin, P, Sehgal, L, Selvaraj, V, Braun, FK, Mathur, R, Feng, L, Neelapu, SS & Kwak, LW 2014, '⁹⁰Y-ibritumomab tiuxetan radiotherapy as first-line therapy for early stage low-grade B-cell lymphomas, including bulky disease', British Journal of Haematology, vol. 167, no. 2, pp. 207-213. https://doi.org/10.1111/bjh.13021

TY - JOUR

T1 - 90Y-ibritumomab tiuxetan radiotherapy as first-line therapy for early stage low-grade B-cell lymphomas, including bulky disease

AU - Samaniego, Felipe

AU - Berkova, Zuzana

AU - Romaguera, Jorge E.

AU - Fowler, Nathan

AU - Fanale, Michelle A.

AU - Pro, Barbara

AU - Shah, Jatin J.

AU - Mclaughlin, Peter

AU - Sehgal, Lalit

AU - Selvaraj, Vijairam

AU - Braun, Frank K.

AU - Mathur, Rohit

AU - Feng, Lei

AU - Neelapu, Sattva S.

AU - Kwak, Larry W.

PY - 2014/10/1

Y1 - 2014/10/1

N2 - 90Y-ibritumomab-tiuxetan (90YIT) was used as a first-line therapy for patients with early-stage follicular lymphoma (FL) or marginal zone B-cell lymphoma (MZL). Thirty-one patients were treated, with an overall 3-month response rate of 100% (68% complete response, 29% unconfirmed complete response and 3% partial response). At a median follow-up of 56 months, ten patients (32%) had disease relapse or progression. The progression-free rates at 3 and 5 years were lower in males, patients with FL, stage II diseaseand non-bulky disease, although they did not reach statistical significance. Grade 3-4 neutropenia, thrombocytopenia and anaemia were 61%, 35%, and 3%, respectively. 90YIT was well tolerated, including in those patients over 60 years old, and achieved high response rates in patients with early-stage low-grade B-cell lymphomas. Bulky disease did not adversely affect tumour response.

AB - 90Y-ibritumomab-tiuxetan (90YIT) was used as a first-line therapy for patients with early-stage follicular lymphoma (FL) or marginal zone B-cell lymphoma (MZL). Thirty-one patients were treated, with an overall 3-month response rate of 100% (68% complete response, 29% unconfirmed complete response and 3% partial response). At a median follow-up of 56 months, ten patients (32%) had disease relapse or progression. The progression-free rates at 3 and 5 years were lower in males, patients with FL, stage II diseaseand non-bulky disease, although they did not reach statistical significance. Grade 3-4 neutropenia, thrombocytopenia and anaemia were 61%, 35%, and 3%, respectively. 90YIT was well tolerated, including in those patients over 60 years old, and achieved high response rates in patients with early-stage low-grade B-cell lymphomas. Bulky disease did not adversely affect tumour response.

KW - Follicular

KW - Marginal zone

KW - Myelosuppression

KW - Radiation

KW - Zevalin

UR - http://www.scopus.com/inward/record.url?scp=84908499170&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84908499170&partnerID=8YFLogxK

U2 - 10.1111/bjh.13021

DO - 10.1111/bjh.13021

M3 - Article

C2 - 25040450

AN - SCOPUS:84908499170

SN - 0007-1048

VL - 167

SP - 207

EP - 213

JO - British Journal of Haematology

JF - British Journal of Haematology

IS - 2

ER -